Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination immunotherapy approach using two cytokines with complementary functions. Granulocyte-macrophage colony-stimulating factor (GM-CSF) leads to dendritic cell/macrophage priming and activation, and increases IL-2 receptor expression on T lymphocytes. Interleukin-2 (IL-2) creates lymphokine-activated killer cells and tumor-infiltrating lymphocyte cells. The combination has shown synergistic antitumor effects in various cancer types.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on granulocyte-macrophage colony-stimulating factor + interleukin-2.